Vascular calcification contributes significantly to cardiovascular morbidity and mortality. It develops in atherosclerotic lesions in a process closely resembling osteogenesis. Paradoxically, it is associated, age independently, with osteoporosis. The mechanism is unknown. We previously showed that vascular cell calcification is, in fact, osteogenic differentiation, ultimately leading to bone tissue formation. The guiding hypothesis of this proposal is that some critical regulator(s) of skeletal bone metabolism also regulate, in a reciprocal manner, bone formation in the artery wall. Two of the major regulators are RANKL, a TNF-alpha superfamily member, and OPG, its soluble decoy receptor. In bone, RANKL promotes bone resorption by osteoclasts, which are abundant in this tissue. In the vasculature, however, where osteoclasts are rare, RANKL treatment does not promote resorption, but, more importantly, it appears to actively promote calcification. One possible mechanism for active calcification by RANKL may lie in its known activation of NF-kB. In chondrocytes, it has been shown that NF-kB induces the potent osteogenic factor, BMP-2. We propose that this pathway may be responsible, in part, for vascular calcification and its paradoxical association with osteoporosis. Significant recent evidence supports this hypothesis: 1) RANKL is upregulated, and OPG is downregulated, in calcified arteries, 2) mice deficient in OPG develop vascular calcification, and 3) RANKL induces osteogenesis and mineralization in valvular myofibroblastic cells. In preliminary studies, we have found that in vitro vascular cell calcification is induced by RANKL and inhibited by OPG. We also found that atherogenic lipids and hyperlipidemia inhibit OPG expression, which would leave RANKL activity unopposed. This mechanism offers a unified explanation for the paradoxical effects of atherogenic factors on biomineralization in bone and in the artery wall. We hypothesize that RANKL stimulates, and OPG inhibits, vascular calcification and that atherogenic lipids increase RANKL activity.
In Aim 1, we will test whether vascular calcification in OPG deficiency results from unopposed RANKL activity and upregulation of BMP-2. We will also test whether another OPG ligand, TRAIL, contributes to calcification by sequestering OPG.
In Aim 2, we will test whether atherogenic lipid inhibition of OPG expression results in unopposed RANKL activity. As a corollary, we will also test whether OPG treatment prevents atherosclerotic calcification.
In Aim 3, we will test the hypothesis that RANKL directly induces vascular calcification in vivo by generating transgenic mice with RANKL overexpression in the vasculature (SM22-rankl(tg) mice). We will use a vascular-specific promoter to avoid the confounding effects of a bone phenotype. These proposed studies will elucidate the roles of RANKL and OPG in vascular calcification and may define a new therapeutic paradigm for calcific vascular disease. Artery wall calcification contributes to cardiovascular disease, and it paradoxically occurs in conjunction with osteoporosis. Based on new supportive evidence, this research will test whether specific regulatory factors that promote loss of mineral from bone also promote gain of mineral in the artery wall.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL081202-05
Application #
7805507
Study Section
Special Emphasis Panel (ZRG1-CVS-B (02))
Program Officer
Srinivas, Pothur R
Project Start
2006-05-01
Project End
2012-04-30
Budget Start
2010-05-01
Budget End
2012-04-30
Support Year
5
Fiscal Year
2010
Total Cost
$375,049
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Sallam, Tamer; Cheng, Henry; Demer, Linda L et al. (2013) Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci 70:3187-97
Chen, Ting-Hsuan; Zhu, Xiaolu; Pan, Leiting et al. (2012) Directing tissue morphogenesis via self-assembly of vascular mesenchymal cells. Biomaterials 33:9019-26
Chen, Ting-Hsuan; Hsu, Jeffrey J; Zhao, Xin et al. (2012) Left-right symmetry breaking in tissue morphogenesis via cytoskeletal mechanics. Circ Res 110:551-9
Chen, Ting-Hsuan; Guo, Chunyan; Zhao, Xin et al. (2012) Patterns of periodic holes created by increased cell motility. Interface Focus 2:457-64
Li, Rongsong; Mittelstein, David; Lee, Juhyun et al. (2012) A dynamic model of calcific nodule destabilization in response to monocyte- and oxidized lipid-induced matrix metalloproteinases. Am J Physiol Cell Physiol 302:C658-65
Pirih, Flavia; Lu, Jinxiu; Ye, Fei et al. (2012) Adverse effects of hyperlipidemia on bone regeneration and strength. J Bone Miner Res 27:309-18
Wong, Margaret N; Nguyen, Timothy P; Chen, Ting-Hsuan et al. (2012) Preferred mitotic orientation in pattern formation by vascular mesenchymal cells. Am J Physiol Heart Circ Physiol 303:H1411-7
Cheng, Henry; Reddy, Aneela; Sage, Andrew et al. (2012) Focal high cell density generates a gradient of patterns in self-organizing vascular mesenchymal cells. J Vasc Res 49:441-6
Morony, S; Sage, A P; Corbin, T et al. (2012) Enhanced mineralization potential of vascular cells from SM22*-Rankl (tg) mice. Calcif Tissue Int 91:379-86
Sage, Andrew P; Lu, Jinxiu; Tintut, Yin et al. (2011) Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 79:414-22

Showing the most recent 10 out of 31 publications